Press Releases

Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)

Award Will Support the First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy  SAN DIEGO, May 15, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California…

Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease

First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety…

Aspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study

Screening Study to Include Multiple Objective Measures of Active and Passive Symptom Capture from Parkinson’s Disease Impact on Motor Function SAN DIEGO, Aug. 24, 2023 /PRNewswire/ —  Aspen Neuroscience today announced that it is partnering with Emerald Innovations, a pioneer in the…

Preclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona

SAN DIEGO, July 6, 2023 /PRNewswire/ — On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for…

Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

SAN DIEGO, Apr. 1, 2020 /PRNewswire/ — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

Aspen Neuroscience announces board of directors and scientific advisory board

SAN DIEGO, Jan. 9, 2020 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, has announced the members of its Board of Directors and Scientific Advisory Board. These boards bring together many of the world’s most distinguished industry and academic minds to deliver Aspen’s personalized cell therapy to persons suffering with Parkinson disease.

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ — Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round — led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32 — to develop the first autologous cell therapies for Parkinson’s disease.

First-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Station

LOUISVILLE, December 02, 2019, 10:00 AM EST — (BUSINESS WIRE) — The National Stem Cell Foundation (NSCF) announced today that research teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services (CRS-19) mission, scheduled to launch December 4th from the Kennedy Space Center in Cape Canaveral, Florida.


Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.